ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Increased Survival after Treatment of Canine Hemangiosarcoma with Fenofibrate

Journal: International Journal of Veterinary Science and Research (Vol.1, No. 1)

Publication Date:

Authors : ; ;

Page : 008-010

Keywords : Dog; Fenofibrate; Hemangiosarcoma; Spleen;

Source : Downloadexternal Find it from : Google Scholarexternal


Hemangiosarcoma (HSA) is a common and highly metastatic tumor that affects predominantly large-breed dogs. The median survival time for dogs diagnosed with splenic HSA without adjuvant chemotherapy after surgery is 86 days. Fenofibrate is an FDA-approved drug commonly utilized to treat high cholesterol and high triglyceride levels in humans. However, fenofibrate has also been shown to possess anti-proliferative and anti-metastatic properties against several aggressive and highly metastatic tumors in vitro and in small animal models. We report a case of a 6.5-year-old dog diagnosed with a splenic hemangiosarcoma and treated solely with micronized fenofibrate, administered orally once a day following splenectomy. The dog survived for over 26 months (804 days) after initial diagnosis without signs of adverse effects due to fenofibrate treatment.

Last modified: 2019-04-12 19:11:11